Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy

S. Dallorso, M. Berger, I. Caviglia, T. Emanueli, M. Faraci, L. Scarso, F. Fagioli, R. Haupt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of this study was to assess the efficacy of an injection of 100 μg/kg of pegfilgrastim in haematopoietic recovery and mobilization in children following 32 courses of chemotherapy. End points were duration of neutropaenia, myeloid recovery and PBMC collection. Neutropaenia lasted a mean of 4.7 days (±2.13 days). Myeloid recovery occurred at a median of 10 days (inter quartile range (IQR) 8-11). Febrile neutropaenia complicated 13 courses (40.6%). Mobilization was observed in 20 out of 26 assessable courses (76.9%). The rise in CD34+ cells occurred at a median of 6 days (IQR 4-7) after PEG and remained >20 per μl for 6 days (IQR 4-8), with a median value of 80 per μl (IQR 48-170.5). The median CD34+ cell peak was 165 per μl (IQR 82.5-331), 9 days (range 6-14) after PEG. PBMC were collected on average at day +5 (+4 to +9) after PEG. In 93.3% of collections, at least 3 × 106 per kg CD34+ cells were collected through a single apheresis. Myeloid recovery occurred in all cases within 15 days, without concomitant thrombocytopaenia. The incidence of primary febrile episodes is in line with data in the literature and with our own historical experience. A long-lasting period of circulating CD34+ cells allowed for more accurate scheduling of apheresis.

Original languageEnglish
Pages (from-to)507-513
Number of pages7
JournalBone Marrow Transplantation
Volume42
Issue number8
DOIs
Publication statusPublished - 2008

Fingerprint

Safety
Drug Therapy
Blood Component Removal
Neoplasms
Fever
Injections
pegfilgrastim
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. / Dallorso, S.; Berger, M.; Caviglia, I.; Emanueli, T.; Faraci, M.; Scarso, L.; Fagioli, F.; Haupt, R.

In: Bone Marrow Transplantation, Vol. 42, No. 8, 2008, p. 507-513.

Research output: Contribution to journalArticle

@article{05446c0bacbd4069b2e15eefc58e0f10,
title = "Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy",
abstract = "The objective of this study was to assess the efficacy of an injection of 100 μg/kg of pegfilgrastim in haematopoietic recovery and mobilization in children following 32 courses of chemotherapy. End points were duration of neutropaenia, myeloid recovery and PBMC collection. Neutropaenia lasted a mean of 4.7 days (±2.13 days). Myeloid recovery occurred at a median of 10 days (inter quartile range (IQR) 8-11). Febrile neutropaenia complicated 13 courses (40.6{\%}). Mobilization was observed in 20 out of 26 assessable courses (76.9{\%}). The rise in CD34+ cells occurred at a median of 6 days (IQR 4-7) after PEG and remained >20 per μl for 6 days (IQR 4-8), with a median value of 80 per μl (IQR 48-170.5). The median CD34+ cell peak was 165 per μl (IQR 82.5-331), 9 days (range 6-14) after PEG. PBMC were collected on average at day +5 (+4 to +9) after PEG. In 93.3{\%} of collections, at least 3 × 106 per kg CD34+ cells were collected through a single apheresis. Myeloid recovery occurred in all cases within 15 days, without concomitant thrombocytopaenia. The incidence of primary febrile episodes is in line with data in the literature and with our own historical experience. A long-lasting period of circulating CD34+ cells allowed for more accurate scheduling of apheresis.",
author = "S. Dallorso and M. Berger and I. Caviglia and T. Emanueli and M. Faraci and L. Scarso and F. Fagioli and R. Haupt",
year = "2008",
doi = "10.1038/bmt.2008.206",
language = "English",
volume = "42",
pages = "507--513",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy

AU - Dallorso, S.

AU - Berger, M.

AU - Caviglia, I.

AU - Emanueli, T.

AU - Faraci, M.

AU - Scarso, L.

AU - Fagioli, F.

AU - Haupt, R.

PY - 2008

Y1 - 2008

N2 - The objective of this study was to assess the efficacy of an injection of 100 μg/kg of pegfilgrastim in haematopoietic recovery and mobilization in children following 32 courses of chemotherapy. End points were duration of neutropaenia, myeloid recovery and PBMC collection. Neutropaenia lasted a mean of 4.7 days (±2.13 days). Myeloid recovery occurred at a median of 10 days (inter quartile range (IQR) 8-11). Febrile neutropaenia complicated 13 courses (40.6%). Mobilization was observed in 20 out of 26 assessable courses (76.9%). The rise in CD34+ cells occurred at a median of 6 days (IQR 4-7) after PEG and remained >20 per μl for 6 days (IQR 4-8), with a median value of 80 per μl (IQR 48-170.5). The median CD34+ cell peak was 165 per μl (IQR 82.5-331), 9 days (range 6-14) after PEG. PBMC were collected on average at day +5 (+4 to +9) after PEG. In 93.3% of collections, at least 3 × 106 per kg CD34+ cells were collected through a single apheresis. Myeloid recovery occurred in all cases within 15 days, without concomitant thrombocytopaenia. The incidence of primary febrile episodes is in line with data in the literature and with our own historical experience. A long-lasting period of circulating CD34+ cells allowed for more accurate scheduling of apheresis.

AB - The objective of this study was to assess the efficacy of an injection of 100 μg/kg of pegfilgrastim in haematopoietic recovery and mobilization in children following 32 courses of chemotherapy. End points were duration of neutropaenia, myeloid recovery and PBMC collection. Neutropaenia lasted a mean of 4.7 days (±2.13 days). Myeloid recovery occurred at a median of 10 days (inter quartile range (IQR) 8-11). Febrile neutropaenia complicated 13 courses (40.6%). Mobilization was observed in 20 out of 26 assessable courses (76.9%). The rise in CD34+ cells occurred at a median of 6 days (IQR 4-7) after PEG and remained >20 per μl for 6 days (IQR 4-8), with a median value of 80 per μl (IQR 48-170.5). The median CD34+ cell peak was 165 per μl (IQR 82.5-331), 9 days (range 6-14) after PEG. PBMC were collected on average at day +5 (+4 to +9) after PEG. In 93.3% of collections, at least 3 × 106 per kg CD34+ cells were collected through a single apheresis. Myeloid recovery occurred in all cases within 15 days, without concomitant thrombocytopaenia. The incidence of primary febrile episodes is in line with data in the literature and with our own historical experience. A long-lasting period of circulating CD34+ cells allowed for more accurate scheduling of apheresis.

UR - http://www.scopus.com/inward/record.url?scp=55549132250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549132250&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.206

DO - 10.1038/bmt.2008.206

M3 - Article

C2 - 18641682

AN - SCOPUS:55549132250

VL - 42

SP - 507

EP - 513

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -